{"id":"NCT03040999","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","officialTitle":"A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-05","primaryCompletion":"2022-05-31","completion":"2024-08-21","firstPosted":"2017-02-02","resultsPosted":"2023-06-08","lastUpdate":"2025-08-27"},"enrollment":804,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Head and Neck Neoplasms"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["KEYTRUDA速"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":["Platinol速","Platinol速-AQ"]},{"type":"RADIATION","name":"Accelerated Fractionation (AFX) Radiotherapy","otherNames":[]},{"type":"RADIATION","name":"Standard Fractionation (SFX) Radiotherapy","otherNames":[]}],"arms":[{"label":"Pembrolizumab + Cisplatin + CRT","type":"EXPERIMENTAL"},{"label":"Placebo + Cisplatin + CRT","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS).","primaryOutcome":{"measure":"Event-free Survival (EFS)","timeFrame":"Up to approximately 62 months","effectByArm":[{"arm":"Pembrolizumab + CRT + Pembrolizumab","deltaMin":null,"sd":null},{"arm":"Placebo + CRT + Placebo","deltaMin":46.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0429"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":151,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","France","Germany","Israel","Italy","Japan","Netherlands","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (T端rkiye)","United Kingdom"]},"refs":{"pmids":["38561010","32490686"],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":245,"n":398},"commonTop":["Radiation skin injury","Stomatitis","Nausea","Anaemia","Dry mouth"]}}